An immunofixation blood test looks for abnormal, identical antibodies or antibody fragments made by one clone of plasma cells or B cells. These proteins are called monoclonal proteins, M proteins, paraproteins, or monoclonal immunoglobulins. The test is especially useful because it can confirm that an abnormal protein is truly monoclonal and identify its immunoglobulin type, such as IgG kappa or IgA lambda. Immunofixation is commonly ordered after an abnormal serum protein electrophoresis result, but it may also be included in the initial workup when multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), AL amyloidosis, or another plasma-cell disorder is suspected. A positive result does not by itself mean cancer. Doctors interpret it with the amount of M protein, serum free light chains, blood counts, kidney function, calcium, symptoms, imaging, and sometimes bone marrow testing. The exact pattern and the clinical context matter more than a simple positive-or-negative label.
- What it measures: Serum immunofixation identifies whether a monoclonal immunoglobulin is present and determines its heavy-chain and light-chain type.
- What a positive result means: A monoclonal band can occur with MGUS, multiple myeloma, Waldenström macroglobulinemia, AL amyloidosis, and other clonal B-cell or plasma-cell disorders.
- What a negative result means: No monoclonal protein was detected by this method, but very low-level, light-chain-only, or nonsecretory disease may require other tests.
- Preparation: The blood draw usually needs no fasting or special preparation unless other tests ordered at the same time require it.
- Key follow-up: Results are usually interpreted alongside SPEP, quantitative immunoglobulins, serum free light chains, and sometimes urine studies or bone marrow evaluation.
Table of Contents
- What the Immunofixation Blood Test Measures
- Why Immunofixation Is Ordered
- How the Test Is Performed and How to Prepare
- Understanding Immunofixation Results
- Conditions Linked to Monoclonal Proteins
- Immunofixation vs. SPEP and Other Protein Tests
- What Happens After an Abnormal Result
What the Immunofixation Blood Test Measures
Immunofixation electrophoresis, often shortened to IFE, is a laboratory method used to identify a monoclonal immunoglobulin in blood. Immunoglobulins are antibodies. A normal immune system makes a wide variety of antibodies through many different B-cell and plasma-cell clones, so the antibody pattern is normally broad and mixed, or polyclonal.
A monoclonal gammopathy is different. One abnormal clone produces a large population of immunoglobulins that are essentially identical. Immunofixation can show that this protein is monoclonal and can identify which parts of the antibody it contains.
Most intact immunoglobulins have two components:
- A heavy chain, usually IgG, IgA, or IgM; less commonly IgD or IgE.
- A light chain, either kappa (κ) or lambda (λ).
A report may therefore describe a pattern such as IgG kappa monoclonal protein, IgA lambda monoclonal protein, or IgM kappa monoclonal protein. Some disorders make only free light chains rather than a complete antibody. In those cases, immunofixation may identify a kappa or lambda light-chain pattern without a corresponding heavy chain.
The test is mainly qualitative: it answers “Is there a monoclonal protein, and what type is it?” It is not the best test for measuring exactly how much of that protein is present. That distinction is why doctors often pair immunofixation with serum protein electrophoresis (SPEP), which is better suited to detecting and quantifying a visible M-spike.
The term “M protein” does not refer to one specific molecule. It is a general label for a monoclonal immunoglobulin or immunoglobulin component produced by a clonal cell population. A separate guide to the M protein blood test explains how the quantity and trend of that protein are used in plasma-cell disorders.
Why Immunofixation Is Ordered
Doctors order serum immunofixation when they need to confirm or characterize a possible monoclonal protein. It may be used because SPEP showed an abnormal band or spike, because another blood test suggested an unusual immunoglobulin pattern, or because symptoms raise concern for a plasma-cell or B-cell disorder even when SPEP is not clearly abnormal.
Common reasons include:
- Unexplained anemia
- Persistent bone pain or fractures
- High blood calcium
- Kidney dysfunction or significant protein in the urine
- Recurrent infections or unusually low normal immunoglobulins
- Unexplained peripheral neuropathy
- High total protein or globulin levels
- A large gap between total protein and albumin
- Suspicion of AL amyloidosis
- Follow-up of a previously diagnosed monoclonal gammopathy
Immunofixation is also used to help classify the abnormal protein after a monoclonal gammopathy has already been detected. The isotype can contribute to diagnostic reasoning. For example, an IgM monoclonal protein often leads clinicians to consider disorders such as Waldenström macroglobulinemia or other B-cell lymphoproliferative conditions, while IgG and IgA monoclonal proteins are common in plasma-cell disorders such as MGUS and multiple myeloma.
The test should not be viewed as a general cancer screen. Many people with a small monoclonal protein have MGUS, a common precursor condition that does not meet criteria for cancer and may never progress. Conversely, some clinically important plasma-cell disorders produce only small amounts of circulating protein. The meaning depends on the complete workup rather than the presence of one band.
When multiple myeloma is a concern, clinicians usually evaluate several laboratory and clinical features together. A multiple myeloma test panel commonly combines monoclonal protein testing with blood counts, kidney function, calcium, and disease-specific assessment rather than relying on immunofixation alone.
How the Test Is Performed and How to Prepare
Serum immunofixation requires a standard blood sample, usually drawn from a vein in the arm. The laboratory separates serum from blood cells and then separates serum proteins according to their physical properties. Antisera directed against specific heavy and light chains are applied. If a monoclonal immunoglobulin is present, a discrete matching band appears in the relevant lanes.
The blood draw itself takes only a few minutes. Most people can eat, drink, and take their usual medicines unless the clinician has ordered other tests that require fasting or medication adjustments. Do not stop prescribed medicines simply because an immunofixation test is scheduled.
One medication issue is important for interpretation: some therapeutic monoclonal antibodies used to treat cancer or inflammatory disease can appear as protein bands and may resemble a patient’s own M protein on traditional electrophoresis-based methods. Drugs used in myeloma treatment, including certain monoclonal antibodies, can create this problem. Laboratories and hematologists may use the treatment history, specialized reflex assays, or mass-spectrometry methods to distinguish drug-related signals from the disease protein.
Sample quality can also matter. Marked hemolysis or other pre-analytical problems may complicate some laboratory measurements, although the larger challenge with immunofixation is usually interpretation rather than collection.
Turnaround varies by laboratory. Results may be available in one to several business days, but complex samples can require additional testing. The report often contains descriptive wording rather than a single numeric value.
Serum vs. urine immunofixation
Immunofixation can be performed on serum or urine. Serum testing is convenient and sensitive for many intact monoclonal proteins. Urine testing can be useful when free light chains are being excreted by the kidneys, particularly in selected patients with suspected or known plasma-cell disorders.
A clinician may request a 24-hour urine collection with electrophoresis and immunofixation when urinary monoclonal protein needs to be assessed. This is different from a routine urinalysis. The urine protein electrophoresis test is often discussed together with urine immunofixation because the two methods provide complementary information.
Understanding Immunofixation Results
The most useful way to read an immunofixation report is to separate three questions: Was a monoclonal protein detected? What immunoglobulin type was identified? How does that finding fit with the amount of protein and the rest of the patient’s evaluation?
| Typical report wording | General meaning | Common next step |
|---|---|---|
| No monoclonal protein detected | No discrete monoclonal immunoglobulin was identified by serum IFE | Interpret with SPEP, free light chains, symptoms, and pretest probability |
| IgG kappa monoclonal protein | A clonal IgG protein using kappa light chains is present | Quantify the M protein and assess for MGUS, myeloma, or another plasma-cell disorder |
| IgA lambda monoclonal protein | A clonal IgA protein using lambda light chains is present | Review SPEP pattern, immunoglobulin levels, free light chains, and clinical findings |
| IgM monoclonal protein | A clonal IgM immunoglobulin is present | Consider IgM MGUS, Waldenström macroglobulinemia, or another B-cell disorder |
| Monoclonal free kappa or lambda light chain | A clonal light-chain process may be present without an intact heavy chain | Check serum free light chains, kidney function, urine studies, and disease-specific testing |
A positive result is not a cancer diagnosis
A positive immunofixation result proves that a monoclonal immunoglobulin pattern is detectable, not that a person has multiple myeloma. MGUS is much more common than myeloma, especially with increasing age. Other monoclonal gammopathies range from asymptomatic precursor states to conditions that damage organs despite a small clonal burden.
The amount of M protein, bone marrow plasma-cell percentage, free light-chain ratio, kidney function, calcium level, hemoglobin, imaging findings, and evidence of organ injury help determine where a patient falls on that spectrum.
A negative result does not exclude every plasma-cell disorder
Serum immunofixation is more sensitive than SPEP for small monoclonal proteins, but no single blood test detects every case. Light-chain disorders may be better recognized with a serum free light chain test. Rare nonsecretory or very low-secretory myeloma may produce little or no measurable monoclonal protein in blood or urine. AL amyloidosis can also require a combination of serum and urine immunofixation plus free light-chain testing.
A clinician therefore interprets a “negative” report in the context of why testing was ordered. If suspicion is low and other studies are normal, a negative result can be reassuring. If symptoms or organ findings remain concerning, further evaluation may still be appropriate.
There is no universal “normal range” for immunofixation
Unlike glucose or calcium, immunofixation usually does not have a numeric reference interval. The normal finding is typically no monoclonal protein detected. Quantitative values on the same report may refer to immunoglobulin concentrations or other tests, not to immunofixation itself.
Conditions Linked to Monoclonal Proteins
A monoclonal protein can accompany several different diseases and precursor states. The same immunofixation pattern can have very different significance depending on protein quantity, symptoms, organ effects, and bone marrow findings.
MGUS is an asymptomatic monoclonal gammopathy that does not meet criteria for multiple myeloma or another overt lymphoid malignancy. It is monitored because a small percentage of patients progress over time. Risk depends on factors such as M-protein concentration, immunoglobulin type, and serum free light-chain ratio.
Smoldering multiple myeloma has a larger clonal plasma-cell burden than MGUS but lacks myeloma-defining organ damage or biomarker criteria that would establish active myeloma. It requires closer surveillance because progression risk is higher.
Multiple myeloma is a plasma-cell cancer diagnosed using bone marrow or tissue evidence of a clonal plasma-cell process plus specific myeloma-defining events. These can include classic CRAB features—hypercalcemia, renal impairment, anemia, and bone lesions—or certain validated biomarkers of malignancy. Immunofixation contributes to the laboratory picture but cannot establish the diagnosis by itself.
AL amyloidosis occurs when a clonal plasma-cell population produces abnormal light chains that misfold and deposit in organs. The amount of monoclonal protein may be small, so combined testing with serum immunofixation, urine immunofixation, and free light chains is particularly important when AL amyloidosis is suspected.
Waldenström macroglobulinemia and related B-cell disorders commonly produce an IgM monoclonal protein. Symptoms can result from marrow involvement, enlarged lymph nodes or spleen, neuropathy, or high serum viscosity.
Some patients have a monoclonal protein linked to kidney, nerve, skin, or other organ injury without meeting conventional criteria for myeloma or lymphoma. These situations are sometimes described by terms such as monoclonal gammopathy of renal significance or monoclonal gammopathy of clinical significance. They show why the size of the M protein is not the only measure of importance.
Immunofixation vs. SPEP and Other Protein Tests
Immunofixation works best as part of a complementary testing strategy. SPEP, IFE, serum free light chains, quantitative immunoglobulins, and urine studies answer different questions.
| Test | Main purpose | Important limitation |
|---|---|---|
| SPEP | Detects and often quantifies an M-spike | Can miss small monoclonal proteins and does not reliably type the immunoglobulin |
| Serum immunofixation | Confirms monoclonality and identifies heavy- and light-chain type | Primarily qualitative rather than a precise quantification method |
| Serum free light chains | Measures free kappa and lambda chains and their ratio | Kidney disease and inflammation can alter concentrations and complicate interpretation |
| Quantitative immunoglobulins | Measures total IgG, IgA, and IgM concentrations | Does not by itself prove that an immunoglobulin increase is monoclonal |
| Urine electrophoresis/immunofixation | Detects and characterizes urinary monoclonal protein | Collection can be inconvenient and results depend on renal handling of proteins |
A common diagnostic strategy uses SPEP, serum immunofixation, and serum free light chains together because their strengths overlap. SPEP can show the quantity of a prominent M protein, immunofixation determines its identity, and free light-chain testing improves detection of light-chain-predominant disorders.
Newer mass-spectrometry methods can detect and characterize monoclonal proteins with greater analytical sensitivity in some settings. They may also help distinguish a patient’s M protein from therapeutic monoclonal antibodies. These methods are increasingly important in specialized centers, but conventional electrophoresis, immunofixation, and free light-chain testing remain widely used and clinically established.
What Happens After an Abnormal Result
An abnormal immunofixation result usually leads to classification and risk assessment, not an immediate assumption of cancer. The next steps depend on why the test was ordered, the monoclonal protein type, the M-protein amount, the free light-chain ratio, and whether there are signs of organ damage.
A typical evaluation may include:
- Confirming and quantifying the protein. SPEP can estimate the M-spike when it is measurable, while quantitative immunoglobulins and serum free light chains add context.
- Checking for organ effects. A complete blood count, creatinine or estimated glomerular filtration rate, calcium, and sometimes urine protein measurements look for anemia, kidney injury, and hypercalcemia.
- Reviewing symptoms and examination findings. Bone pain, fatigue, infections, neuropathy, weight loss, edema, bruising, and other findings can influence urgency and test selection.
- Considering imaging. Low-dose whole-body CT, PET/CT, MRI, or other imaging may be used when myeloma or bone disease is suspected.
- Deciding whether bone marrow testing is needed. A marrow biopsy can measure clonal plasma cells and provide flow cytometry, cytogenetic, and molecular information when the probability of a clinically significant plasma-cell disorder warrants it.
People with low-risk MGUS may need only periodic monitoring after the initial evaluation. The interval depends on the risk profile and clinician judgment. A rising M protein, increasingly abnormal free light-chain ratio, new anemia, worsening kidney function, high calcium, or new bone symptoms may prompt faster reassessment.
Contact the treating clinician promptly if an abnormal monoclonal protein result is accompanied by worsening weakness, confusion, dehydration, severe bone pain, new neurologic symptoms, reduced urine output, or other significant symptoms. These findings have many possible causes, but they may indicate complications that need timely evaluation.
The most useful question after receiving an immunofixation result is not simply “Is it positive?” Ask what protein was found, how much monoclonal protein is present on related tests, whether the free light-chain ratio is abnormal, whether there is evidence of organ injury, and what follow-up interval or additional testing is appropriate.
References
- Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance: A Review 2025 (Review)
- Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management 2024 (Review)
- Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part I: Update on laboratory tests for the study of monoclonal gammopathies 2023 (Guideline)
- Laboratory and Clinical Settings of Heavy/Light Chain (HLC) Assays in the Management of Monoclonal Gammopathies and Multiple Myeloma 2023 (Review)
- Multiple Myeloma: A Structured and Multidisciplinary Approach to Diagnosis 2026 (Review)
Disclaimer
This article provides general information about serum immunofixation and monoclonal protein testing and is not a diagnosis or a substitute for medical care. A monoclonal protein can have benign, precancerous, or malignant causes, so results should be interpreted with related laboratory tests, symptoms, and clinical findings. Seek medical advice promptly for significant symptoms or newly abnormal kidney function, calcium, blood counts, or neurologic findings.
